Clinical Trials Logo

Necrosis clinical trials

View clinical trials related to Necrosis.

Filter by:

NCT ID: NCT03410940 Terminated - Clinical trials for Rheumatoid Arthritis

PMCF Study of the CLS Brevius Stem With Kinectiv Technology

Start date: January 7, 2011
Phase:
Study type: Observational

This study is a multi-center, prospective, non-controlled post-market surveillance study. The primary objective of this study is to confirm the safety and performance of the CLS Brevius stem with Kinectiv technology by obtaining implant survivorship and clinical outcomes data for the commercially available stem.

NCT ID: NCT03382665 Terminated - Clinical trials for Rheumatoid Arthritis

Post-market Surveillance Study With the HYPERION Hip Endoprosthesis System in Defect Reconstruction

Start date: January 2010
Phase:
Study type: Observational

The study is a multi-center, prospective, non-controlled, consecutive cohort post market surveillance study. The objective of this study is to obtain survival and clinical outcome data on the Hyperion® system in primary and revision total hip arthroplasty.

NCT ID: NCT03245320 Terminated - Clinical trials for Rheumatoid Arthritis

Clinical Evaluation of the TITAN™ Total Shoulder System

Start date: March 20, 2017
Phase:
Study type: Observational

A post market, non-randomized, multi-center, open-label,clinical study using survivorship to study the safety and efficacy of the Integra® TITAN™ Total Shoulder System 1.0 (TAS) when used for total shoulder arthroplasty.

NCT ID: NCT02862574 Terminated - Clinical trials for Rheumatoid Arthritis

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Start date: December 15, 2016
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of andecaliximab (GS-5745) versus placebo as an add-on therapy to a tumor necrosis factor (TNF) inhibitor and methotrexate in adults with moderate to severe rheumatoid arthritis (RA).

NCT ID: NCT02673541 Terminated - Pancreatic Necrosis Clinical Trials

Study of a Lumen- Apposing, Covered, Self-Expanding Metal Stent (Axios™) Versus Multiple Double Pigtail Stents

Start date: February 2016
Phase: N/A
Study type: Interventional

The present study aims to compare the clinical efficacy and cost effectiveness of the AXIOS™ stent versus the "conventional" approach using double pigtail plastic stents in the treatment of patients with walled-off pancreatic necrosis.

NCT ID: NCT02655120 Terminated - Clinical trials for Aseptic Necrosis of Femur Head

Autologous Bone Marrow and BMP7 Treatment in the Necrosis in the Femoral Head of the Adult

BMP7
Start date: March 2005
Phase: N/A
Study type: Interventional

The main objective of the study is to evaluate the effectiveness of the injection of bone marrow unconcentrated more R BMP 7 to repair necrosis of the femoral head with stage I-III classification FICAT.

NCT ID: NCT02385903 Terminated - Clinical trials for Necrotic Arterial Wounds

Randomized Controlled Trial on the Use of Flammacerium in Necrotic Arterial Wounds of the Lower Limb Versus Standard Treatment

Flammacérium
Start date: September 2009
Phase: Phase 2
Study type: Interventional

Ischemia of an area may lead to a necrotic wound. In lower limb, it especially happens in diabetic or artheriopatic patients. It can lead to an amputation need. Revascularization procedure cannot be provide in all cases. Flammacerium, by a crust training and its anti-inflammatory effect, could stabilize necrosis extension, avoid bacterial contamination and then improve some incapacitating symptoms like odor or pain. This product may allow to delay amputation ruling for patients on who this procedure is unsafe. During 6 months, the investigators evaluate Flammacerium against standard dressing procedure in necrotic wound of the lower limb in patients where no revascularization can be provide. The investigators observed its effect on amputation need, symptoms as pain, infection, wound aspect evolution, wound size decrease.

NCT ID: NCT02220478 Terminated - Clinical trials for Rheumatoid Arthritis

Signature Acetabular Posterior/Lateral Data Collection

Start date: November 2014
Phase: N/A
Study type: Interventional

The primary purpose of this pilot study is to evaluate the accuracy of cup placement between two instrumentation technologies: Cutting Guide and Conventional Instrumentation.

NCT ID: NCT02196818 Terminated - Osteoarthritis Clinical Trials

A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup

Start date: March 2013
Phase:
Study type: Observational

This is a multi-centre, prospective post marketing surveillance study to assess mid-term performance of the Mpact cup in subjects requiring primary total hip arthroplasty.

NCT ID: NCT02114489 Terminated - Hip Necrosis Clinical Trials

Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis

Start date: June 2014
Phase: Phase 3
Study type: Interventional

Aseptic osteonecrosis of the hip (AOH) concern 1 Swiss young adult to 1000 (30-40 years old). They are responsible to a severe joint destruction and in the majority of cases a joint replacement. To the hip, we can distinguish 4 stages of osteonecrosis according to Ficat: 1, 2, 3, 4. Stage 3 and 4 AOH management are unanimous surgical. But management of stage 1 and 2 are unclear. Bisphophonates are mainly used for bone and osteoporosis diseases. They decrease the bone turn over, and the risk of fracture. They also decrease the bone marrow oedema and the pain associated to this oedema. Ibandronate is a bisphosphonate with a rapid effect, a short half-life, easy to manage, and with few side effects. We designed a double-blind prospective randomized trial aiming to evaluate the efficacy of an infusion of ibandronate versus placebo on pain and AOH progression in patients with stage 1 and 2 AOH. Our hypothesis is that there will be a pain reduction >=20 mm on the VAS scale (SD 10mm) in the ibandronate group versus placebo, and a non radiological progression in the treated group.